为什么要开展血友病的免疫学研究？ - Suppr

Suppr

超能文献

Why do immunology research in hemophilia?

作者信息

Scott David W

机构信息

Uniformed Services University of Health Sciences, Bethesda, MD, United States.

出版信息

Cell Immunol. 2016 Mar;301:1. doi: 10.1016/j.cellimm.2015.10.010. Epub 2015 Nov 6.

DOI:10.1016/j.cellimm.2015.10.010

PMID:26893239

Abstract

摘要

相似文献

Why do immunology research in hemophilia?为什么要开展血友病的免疫学研究？

Cell Immunol. 2016 Mar;301:1. doi: 10.1016/j.cellimm.2015.10.010. Epub 2015 Nov 6.

[Incidence of the appearance of factor VIII inhibitor in patients with hemophilia A at the Hemophilia Center of the Clinical Hospital Center in Zagreb].[萨格勒布临床医院中心血友病中心甲型血友病患者中出现凝血因子VIII抑制剂的发生率]

Lijec Vjesn. 1983 Oct;105(10):410-1.

Prevention and treatment of induced antibodies to clotting factors in hemophilia--applications of advances in immunology.血友病中凝血因子诱导抗体的预防与治疗——免疫学进展的应用

Prog Clin Biol Res. 1984;150:155-66.

World registry on factor VIII inhibitor patients: why?

Semin Hematol. 1993 Apr;30(2 Suppl 1):7-9.

[Occurrence of anti-factor VIII antibodies in children with hemophilia].

Acta Haematol Pol. 1987 Jan-Jun;18(1-2):123-6.

HLA-DR and Factor VIII antibodies in hemophilia A.甲型血友病中的人类白细胞抗原-DR和凝血因子VIII抗体。

Thromb Haemost. 1984 Apr 30;51(2):293.

Proteolytic antibodies against factor VIII in hemophilia A.

N Engl J Med. 2002 Feb 28;346(9):702-3. doi: 10.1056/NEJM200202283460911.

HLA antigens and factor VIII antibody in classic hemophilia. European study group of factor VIII antibody.经典血友病中的HLA抗原与凝血因子VIII抗体。凝血因子VIII抗体欧洲研究小组

Thromb Haemost. 1981 Dec 23;46(4):687-9.

Hemophilia.血友病

N Engl J Med. 2001 Oct 4;345(14):1066; author reply 1067.

Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.

Thromb Haemost. 1999 Mar;81(3):475-6.

引用本文的文献

Diverse potential of chimeric antigen receptor-engineered cell therapy: Beyond cancer.嵌合抗原受体工程细胞疗法的多样潜力：超越癌症。

Clin Transl Med. 2025 Apr;15(4):e70306. doi: 10.1002/ctm2.70306.

Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo.工程化表达 FVIII 的细胞毒性 T 细胞在体外和体内靶向并杀伤 FVIII 特异性 B 细胞。

Blood Adv. 2018 Sep 25;2(18):2332-2340. doi: 10.1182/bloodadvances.2018018556.

Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy.甲型血友病抑制剂治疗：工程化T细胞疗法的前景。

Transl Res. 2017 Sep;187:44-52. doi: 10.1016/j.trsl.2017.06.002. Epub 2017 Jun 9.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验